1. Gilead says remdesivir cut risk of COVID patient death in clinical trial — BioNTech-Pfizer COVID vaccine expected to be ready for approval by year end — LEO Pharma eyeing 2021 launch for Dupixent rival — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Great Idea Wrong People

Discussion in 'Auriga Labs' started by Anonymous, Jun 24, 2011 at 3:22 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Auriga had a great idea, they just had the wrong people, especially Richard and Phil. What a pair.
     

  2. Anonymous

    Anonymous Guest

    Agreed. A great idea poorly executed. The assumption that something that sells in Europe will automatically sell in the United States was a huge miscalculation. They also had cold medication that they knew was going to be pulled from the market.